Cladribine activity in systemic mast cell disease: Application of biochemistry in the modern era of molecular biology

Leukemia Research

Volumn 28, Issue 2, 2004, Pages 113-114

  Nieva, Jorge ^a   Saven, Alan ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ADENOSINE DEAMINASE; ANTIHISTAMINIC AGENT; CLADRIBINE; CORTICOSTEROID; DEOXYADENOSINE TRIPHOSPHATE; DNA; HISTAMINE; IMATINIB; INTERFERON; NICOTINAMIDE ADENINE DINUCLEOTIDE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PSORALEN; RIBONUCLEOTIDE REDUCTASE; STEM CELL FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; B CELL LYMPHOMA; B LYMPHOCYTE; BIOCHEMISTRY; BONE DEMINERALIZATION; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DEPRESSION; DISABILITY; DNA STRAND BREAKAGE; DNA SYNTHESIS INHIBITION; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; EDITORIAL; ENZYME DEFICIENCY; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HAIRY CELL LEUKEMIA; HISTAMINE RELEASE; HISTIOCYTOSIS; HUMAN; HYPEREOSINOPHILIC SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; LANGERHANS CELL; LYMPHOCYTOPENIA; LYMPHOMA; MAST CELL; MAST CELL LEUKEMIA; MASTOCYTOSIS; MOLECULAR BIOLOGY; MONOCYTE; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; ONCOGENE C KIT; PEPTIC ULCER; PRIORITY JOURNAL; PUVA; RASH; SARCOMA; SIDE EFFECT; SKIN MANIFESTATION; SYSTEMIC MASTOCYTOSIS; T CELL LYMPHOMA; T LYMPHOCYTE; URTICARIA PIGMENTOSA;

EID: 0345276001     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(03)00258-3     Document Type: Editorial

References (12)

1. Carson D.A., Wasson D.B., Lakow E., Namatani N. Possible metabolic basis for the different immunodeficient states associated with genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase. Proc. Natl. Acad. Sci. U.S.A. 79:1982;3848-3852.
2. Carson D.A., Kaye J., Seegmiller J.E. Differential sensitivity of human leukemic T cell lines and B cell lines to growth inhibition by deoxyadenosine. J. Immunol. 75:1978;472-476.
3. Saven A., Piro L.D. Newer purine analogs for the treatment of hairy-cell leukemia. N. Engl. J. Med. 330:1994;691-697.
4. Carrera C.J., Saven A., Piro L.D. Purine metabolism of lymphocytes, targets for chemotherapy drug development. Hematol. Oncol. Clin. N. Am. 8:1994;357-381.
5. Santana V.M., Mirro J. Jr., Kearns C., Schell M.J., Crom W., Blakley R.L. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J. Clin. Oncol. 10:1992;364-370.
6. Beutler E., Sipe J.C., Romine J.S., Koziol J.A., McMillan R., Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl. Acad. Sci. U.S.A. 93:1996;1716-1720.
7. Carrera C.J., Terai C., Lotz M., et al. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo a novel approach to immunosuppressive therapy. J. Clin. Invest. 86:1990;1480-1488.
8. Saven A., Burian C. Cladribine activity in adult Langerhans-cell histiocytosis. Blood. 93:1999;4125-4130.
9. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization Classification of Tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001, Chapter 11. p. 291-302.
10. Klion A.D., Noel P., Akin C. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis and imatinib responsiveness. Blood. 101:2003;4660-4666.
11. Zermati Y., De Sepulveda P., Feger F. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene. 22:2003;660-664.
12. Pardanani A., Reeder T., Elliott M., Li C.Y., Tefferi A. Imatinib therapy for systemic mast cell disease. Blood. 100:2002;255. (abstract).